There is a growing interest in the therapeutic potential of cord blood to modulate autoimmune disease. Type 1 diabetes, also referred to as juvenile diabetes, is an autoimmune disease resulting in the destruction of insulin-producing beta cells in the pancreas. Dr. Michael Haller, Assistant Professor of Pediatric Endocrinology at the University of Florida, is currently conducting a second clinical trial to determine whether autologous cord blood stem cell transfusions can
improve glucose control in children with Type 1 diabetes by restoring immune tolerance.